BRAF-mutated, acral verrucous melanoma successfully treated by dabrafenib plus trametinib combination therapy

Clin Exp Dermatol. 2019 Dec;44(8):945-946. doi: 10.1111/ced.13976. Epub 2019 Jun 18.

Authors

T Kiyohara¹, N Nagano¹, M Miyamoto¹, T Shijimaya¹, S Nakamaru¹, K Makimura¹, H Tanimura¹

Affiliation

¹ Department of Dermatology, Kansai Medical University Medical Center, Osaka, Japan.

PMID: 30950075
DOI: 10.1111/ced.13976

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Asian People / genetics
Dermoscopy / methods
Female
Humans
Imidazoles / administration & dosage
Imidazoles / therapeutic use
Lymph Node Excision / methods
Lymph Nodes / pathology
Margins of Excision
Melanoma / drug therapy*
Melanoma / genetics*
Melanoma / pathology
Melanoma / surgery
Middle Aged
Mutation
Neoplasm Staging
Oximes / administration & dosage
Oximes / therapeutic use
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / genetics
Pyridones / administration & dosage
Pyridones / therapeutic use
Pyrimidinones / administration & dosage
Pyrimidinones / therapeutic use
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics
Skin Neoplasms / pathology
Skin Neoplasms / surgery
Treatment Outcome
Warts / genetics
Warts / pathology

Substances

Imidazoles
Oximes
Protein Kinase Inhibitors
Pyridones
Pyrimidinones
trametinib
BRAF protein, human
Proto-Oncogene Proteins B-raf
dabrafenib